Financials
Financial year 2025
EMK PHARM from Elsene, company number BE0784925582, closed financial year 2025 with a result of € 6,295 after tax. For that financial year EMK PHARM recorded a gross margin of € 25,138 and equity of € 4,295. Compared with financial year 2024, the result moved from € 532 to € 6,295. Profitable, and profit is growing. The buffer shrank hard: equity is 76 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 1, 2026.
€ 4,295
▼ 76% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 6,295
▲ € 5,763 vs 2024
Profit after tax over the fiscal year.
€ 1,219
▼ 56% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 20,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 25,108
▼ 35% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 24,433
▼ 29% vs 2024
€ 9,773 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 2,544
▲ 30% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 19,090
▼ 1% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 21,596 | € 20,507 | € 20,048 | € 25,138 | ▲ 25% |
| Profit after taxes | € 13,839 | € 3,629 | € 532 | € 6,295 | ▲ € 5,763 |
| Equity | € 13,839 | € 17,468 | € 18,000 | € 4,295 | ▼ 76% |
| Total debts | € 18,926 | € 63,082 | € 55,380 | € 66,067 | ▲ 19% |
| Cash | € 8,338 | € 15,567 | € 2,766 | € 1,219 | ▼ 56% |
| Retained profit | € 13,839 | € 17,468 | € 18,000 | € 4,295 | ▼ 76% |
| Dividend | € 0 | € 0 | € 0 | € 20,000 | |
| Bank debt | € 0 | € 43,979 | € 34,206 | € 24,433 | ▼ 29% |
| Balance sheet total | € 32,765 | € 80,550 | € 73,379 | € 70,362 | ▼ 4% |
Key figures of EMK PHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EMK PHARM?
What happened at EMK PHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 6,295 (▲ € 5,763 vs 2024). filed late Source: NBB ↗
- New establishment in Elsene. KBO
- Hind El Assiri became a director. NBB
- Soufiane El Mellouki became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 13,839 profit in 2022 to € 6,295 profit in 2025.
Paid € 16,182 in corporate taxes since 2022.
Best year ever: 2022, with € 13,839 profit.
Paid out € 20,000 in dividends to the owners in total.
A new publication or filing at EMK PHARM? We notify you, reason included.
Follow EMK PHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind EMK PHARM are Hind El Assiri and Soufiane El Mellouki.
Directors
According to the 2025 annual accounts
Hind El Assiri
Director
since 2022
Soufiane El Mellouki
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Marsveldplein 5
1050 Elsene
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0784.925.582
- VAT number
- BE 0784.925.582
- Registered office
- Marsveldplein 5, 1050 Elsene
- Names & denominations
- EMK PHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 April 2022
- Peppol
- Active · Active since 3 May 2026
- Activities · NACE
Activiteiten op het gebied van voeding
Overige menselijke gezondheidszorg, n.e.g.
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige zakelijke dienstverlening, neg
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering